New combo therapy shows promise for EGFR-Mutant lung cancer
Disease control
Completed
This study tested whether adding bevacizumab to erlotinib helps people with a specific type of advanced lung cancer (non-small cell lung cancer with EGFR mutations) live longer without their cancer getting worse. About 311 Chinese patients took part. The goal was to see if the co…
Phase: PHASE3 • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated May 14, 2026 12:03 UTC